Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) Vol. 123; no. 4; pp. 451 - 456
Main Authors:	Gaglia, Jr, Michael A, Waksman, Ron
Format:	Journal Article
Language:	English
Published:	United States 01-02-2011
Subjects:	Acute Coronary Syndrome - drug therapy Adenosine - adverse effects Adenosine - analogs & derivatives Adenosine - pharmacokinetics Adenosine - therapeutic use Advisory Committees - legislation & jurisprudence Aspirin - adverse effects Aspirin - therapeutic use Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Drug Approval Humans Multicenter Studies as Topic Platelet Aggregation Inhibitors - pharmacokinetics Platelet Aggregation Inhibitors - therapeutic use Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - pharmacokinetics Purinergic P2Y Receptor Antagonists - therapeutic use Randomized Controlled Trials as Topic Thrombosis - drug therapy Thrombosis - mortality Thrombosis - prevention & control Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use United States United States
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0009-7322 1524-4539
DOI:	10.1161/circulationaha.110.985325